Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
about
KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing.KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-AnalysisSerum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in TaiwanPleural involvement in lung cancer.KRAS mutant lung cancer: progress thus far on an elusive therapeutic target.Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates.Analysis of KRAS and BRAF genes mutation in the central nervous system metastases of non-small cell lung cancerKRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancerAnalysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia.KRAS and the Reality of Personalized Medicine in Non-small Cell Lung Cancer.KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis.Selumetinib for the treatment of non-small cell lung cancer.Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Altered Transcriptional Control Networks with Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models.Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.Prognostic significance of EGFR and KRAS mutations in NSCLC patients with brain metastases treated with radiosurgery†.The efficacy of first-line chemotherapy is associated with KRAS mutation status in patients with advanced non-small cell lung cancer: a meta-analysis.Should KRAS mutation still be used as a routine predictor of response to EGFR-TKIs in advanced non-small-cell lung cancer? A revaluation based on meta-analysis.
P2860
Q33634165-9FC6E2CF-4655-469F-AB3A-48899F07F7F4Q33690682-8CD51B74-4500-4986-8778-BB4EC963E047Q33754779-9AFBC7BB-4F4E-4474-B26E-3181FC353E09Q35034044-781A2529-FCA8-4392-93A1-773A392F10B6Q35196603-6B260A4C-21F2-48B0-9A13-2111320A144FQ35739559-512885CD-41A9-4B8F-8FA9-875A5DA2AE75Q36369197-BBA40492-DE6E-4894-98E3-FC0C2033AB79Q36557569-5B4FA7EC-4C34-4B8A-89B4-6525967B8028Q36733474-D3C46885-C20B-414A-AA69-97C672699EE0Q36834504-E1D85991-482D-40CC-A2FA-9E0815293B5BQ36946809-5F698260-40F6-4C02-A269-3F058EE2AD35Q37246286-312188BD-8AFC-484E-B3E3-8880D9152291Q37272817-7246AC9E-0891-4FD1-A70F-54BEB16C2668Q37353957-92B2FB71-CED6-46ED-BEDE-670DC79FAA60Q37554470-301C4B98-9949-448D-8F3F-C8B1DDF99BE5Q38663069-AC601951-521A-4392-9AB6-EEF94CFA0B41Q38682370-7F06F23A-4F8A-474C-A93B-63472AB9D854Q41582923-7EA91BC5-B5E0-4040-85A3-69A327F42D07Q47147655-4E13EAA3-8790-47A4-9806-7CC5F2534608Q48394926-7A4085BB-4565-4BA5-9A4C-AB5460F1CC9BQ53165144-4783BF21-F08E-4092-BBD4-9EA0A43A3520Q53647606-3045810D-DAAF-42DE-94B4-3A98AD286840
P2860
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@ast
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@en
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@nl
type
label
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@ast
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@en
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@nl
prefLabel
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@ast
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@en
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@nl
P2093
P2860
P1433
P1476
Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer.
@en
P2093
Deok Won Hwang
Jin Seok Ahn
Jong-Mu Sun
Keunchil Park
Myung-Ju Ahn
P2860
P304
P356
10.1371/JOURNAL.PONE.0064816
P407
P577
2013-05-28T00:00:00Z